Xcout Intel
Leucid Bio
Leucid Bio is a privately held clinical-stage biotechnology company headquartered in London, United Kingdom, with research operations based at Guy's Hospital. The firm translates CAR-T cell research originating from King's College London into novel cancer immunotherapies.
Subscribe to see Leucid Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Leucid Bio at a glance
Leucid Bio is a life sciences company headquartered in United Kingdom, founded in 2014. Its most recent funding round, Series A, raised $16M in October 2021. Xcout tracks 10 named people at Leucid Bio, including Filippo Petti (Chief Executive Officer).
Leucid Bio leadership
- Filippo PettiChief Executive Officer
- Mark DochertyCFO & COO
- Ian MiscampbellChairman
- Dr John MaherCSO
- Belinda CarlsenVP Clin Ops
- Marc DaviesVP R&D
4 more named people on record for Leucid Bio, with roles, board committees and tenure — see the full roster →
Leucid Bio funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $16M | 6 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Leucid Bio competitors
A few of Leucid Bio's closest competitors — see the full list of competitors and alternatives →
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Centauri Therapeutics Limited is a privately held immunotherapy company with its primary headquarters located in London, United Kingdom.
Grey Wolf Therapeutics is a biotechnology company headquartered in the UK focused on delivering a new class of treatments to improve the lives of people with cancers and autoimmune disorders.
Alchemab Therapeutics Ltd is a biotechnology company headquartered in London, England, focused on pioneering patient-centric antibody discovery and development.
OneChain Immunotherapeutics is a biotechnology company based in Barcelona focused on the development of CAR-T cell therapies and in vivo platforms for cancer immunotherapy.
Cytospire Therapeutics Limited is a biotechnology research company based in London, United Kingdom. The company is focused on developing a portfolio of next-generation immune cell engagers to improve patients' lives.
Get Leucid Bio's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Leucid Bio in Xcout Intel
- 10 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access